Hypertension Journal

Register      Login

VOLUME 3 , ISSUE 1 ( January-March, 2017 ) > List of Articles

THERAPEUTIC

Device-based Therapies for Resistant Hypertension: Current Status

Mohsin Wali, C Venkata S Ram

Citation Information :

DOI: 10.5005/jp-journals-10043-0070

License: CC BY-ND 4.0

Published Online: 00-00-0000

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Wali M, Ram CVS. Device-based Therapies for Resistant Hypertension: Current Status. Hypertens J 2017;3(1):44-49.


PDF Share
  1. Renal denervation for treatment of drug-resistant hypertension. Trends Cardiovasc Med 2015 Feb;25(2):107-115.
  2. Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. Circulation 2014 Apr;129(13):1440-1451.
  3. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009 Apr;373(9671):1275-1281.
  4. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013 Jul;128(2):132-140.
  5. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010 Dec;376(9756):1903-1909.
  6. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014 Apr;370(15):1391-1401.
  7. Is the failure of Symplicity HTN-3 trial to meet its efficacy endpoint the “end of the road” for renal denervation? J Am Soc Hypertens 2015 Feb;9(2):140-149.
  8. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens 2014 Aug;8(8):593-598.
  9. Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. Hypertension 2014 Sep;64(3):565-572.
  10. Carotid baroreceptor stimulation: a promising approach for the management of resistant hypertension and heart failure. Curr Vasc Pharmacol 2014 Jan;12(1):30-37.
  11. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010 Mar;55(3):619-626.
  12. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos pivotal trial. J Am Coll Cardiol 2011 Aug;58(7):765-773.
  13. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012 Mar-Apr;6(2):152-158.
  14. Baroreflex activation therapy for the treatment of drug-resistant hypertension: new developments. Cardiol Res Pract 2012;2012:587194.
  15. Median nerve modulation: a novel approach to resistant hypertension. J Am Coll Cardiol Interv 2016;9(4_S):S54.
  16. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomized controlled trial. Lancet 2015 Apr;385(9978):1634-1641.
  17. Effects of arteriovenous fistula formation on arterial stiffness and cardiovascular performance and function. Nephrol Dial Transplant 2011 Oct;26(10):3296-3302.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.